---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-063184"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:58:49.723050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave reports positive Phase 2 FORWARD-53 data for WVE-N531 in DMD; plans NDA in 2026

## Summary
- TTR improved 3.8 seconds vs natural history (p<0.05); fibrosis reduced 28.6% (p<0.01); CK declined 50%.
- Mean dystrophin 7.8% (88% >5%); muscle health reversal shown; no SAEs.
- FDA confirms accelerated approval pathway; NDA filing planned in 2026 based on all FORWARD-53 data.
- Monthly dosing supported by 61-day half-life; additional DMD exons (52,51,45,44) CTAs expected in 2026 addressing ~$2.4B US market.
- Pipeline milestones: WVE-006 AATD data, WVE-007 obesity data H2 2025, WVE-003 HD IND H2 2025.

## SEC filing metadata
- accession: 0001193125-25-063184
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525063184/0001193125-25-063184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525063184/d918658d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-063184
- JSON: https://secwatch.observer/filing/0001193125-25-063184.json
- Plain text: https://secwatch.observer/filing/0001193125-25-063184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.